|
**Overview**: Metanephrines Random Urine Panel**Introduction**: The Metanephrines Random Urine Panel is a diagnostic tool designed to screen for pheochromocytoma using urine samples. In India, urinary fractionated metanephrines serve as an alternative to plasma for detecting catecholamine-secreting tumors, with high sensitivity in symptomatic patients or adrenal masses. High morbidity from under-testing in rural/low-SES patients with episodic hypertension or headaches, limited labs, delayed diagnosis leading to cardiovascular complications. Per endocrinology practices aligned with ICMR and Endocrine Society of India guidelines, the test employs spectrophotometry for metanephrine and normetanephrine over 1-2 days with good accuracy, valuable when plasma is unavailable or for confirmation. This diagnostic falls under endocrine screening and targets patients with suspected pheochromocytoma or adrenal incidentaloma, addressing accurate detection to guide alpha-blockade and surgical planning. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling catecholamine metabolite assessment and reducing crisis risk. Its urine-based approach ensures reliable excretion measurement.**Other Names**: Metanephrines U Pnl.**FDA Status**: FDA approved, CLIA certified for biochemistry, compliant with 2025 standards.**Historical Milestone**: Urinary metanephrines standard; in India, used in hypertension workup.**Purpose**: The test assesses 2 parameters including metanephrine to guide pheochromocytoma screening, detect catecholamine excess, inform imaging.**Test Parameters**: 1. Metanephrine, 2. Normetanephrine.**Pretest Condition**: No fasting required; patients should avoid interfering foods/medications.**Specimen**: 10 mL random urine in 1 sterile container, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 24 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on hypertension, sweating, adrenal mass.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undetected pheochromocytoma including crisis, benefits of screening, and minimal discomfort from urine collection.**Procedural Considerations**: The test involves sample processing using spectrophotometry by trained personnel to ensure sterile technique and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, or dietary interference can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Elevated metanephrines/normetanephrines indicate pheochromocytoma, necessitating specialist input.**Specialist Consultation**: Endocrinologists should be consulted for management.**Additional Supporting Tests**: Plasma free metanephrines, CT/MIBG for confirmation.**Test Limitations**: Less sensitive than plasma; comprehensive approach required.**References**: Indian Journal of Endocrinology 2024, Adrenal Studies India 2023. |
